Halozyme Therapeutics, Inc. — FY 2015 Form 10-K
Reporting period: Year ended December 31, 2015; filed February 29, 2016. This is an annual report, not a standalone fourth-quarter filing. Unless noted, amounts are in U.S. dollars.
Business context
Halozyme is a biotechnology company developing oncology therapies and licensing its ENHANZE technology, based on recombinant human hyaluronidase (rHuPH20), to help deliver injected drugs subcutaneously. Its lead proprietary candidate, PEGPH20, is being developed for tumors with high hyaluronan (HA), particularly stage IV pancreatic ductal adenocarcinoma (PDA). Hylenex recombinant is its marketed product. The company reported six ENHANZE collaborations: Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly.
Key financial results
| Metric | 2015 | 2014 |
|---|---|---|
| Total revenue | $135.1 million | $75.3 million |
| Product sales | $46.1 million | $37.8 million |
| Collaboration revenue | $58.0 million | $28.1 million |
| Royalties | $31.0 million | $9.4 million |
| Operating loss | $(27.5) million | $(63.0) million |
| Net loss | $(32.2) million | $(68.4) million |
| Net loss per share | $(0.25) | $(0.56) |
| Cash, cash equivalents and marketable securities at year-end | $108.3 million | $135.6 million |
| Working capital at year-end | $109.3 million | $137.0 million |
Product sales gross profit was $16.8 million, or approximately 36.5% of product sales. Research and development expense rose 17% to $93.2 million, including $75.6 million for PEGPH20, up from $34.9 million in 2014. Selling, general and administrative expense increased 11% to $40.0 million. Interest expense was $5.2 million.
Net cash used in operating activities was $37.1 million, compared with $47.5 million in 2014. Investing activities provided $5.9 million, primarily reflecting marketable-security maturities; financing activities provided $13.1 million, mainly from equity-plan issuances. The company had $49.8 million of 7.55% term debt outstanding at year-end, including $21.9 million classified as current. Total liabilities were $138.8 million.
Material changes and unusual items
- Revenue increased 79%, chiefly reflecting higher royalties from Roche products and $48.0 million of upfront license revenue from AbbVie ($23.0 million) and Lilly ($25.0 million). These upfront payments materially contributed to reported revenue and do not establish a recurring revenue run rate.
- Royalties rose to $31.0 million, primarily as Roche sales of Herceptin SC increased. Roche represented 42% of 2015 revenue; Lilly 19% and AbbVie 17%, together indicating substantial customer concentration.
- The net loss narrowed by $36.1 million, while PEGPH20 R&D spending more than doubled. Quarterly results included net income of $3.0 million in Q2 and $4.3 million in Q4; Q4 revenue was $52.2 million, including Lilly’s $25.0 million license fee. The other quarters reported losses.
- In December 2015, the company entered into a $150 million royalty-backed loan, with funding received in January 2016. It is secured by specified Roche and Baxalta royalties and is non-recourse to Halozyme Therapeutics, Inc. The loan bears interest at 8.75% plus three-month LIBOR, subject to a 0.7% floor and 1.5% cap. Royalties are subject to specified application rules and repayment caps.
Outlook, management commentary and risks
- Management said year-end cash and marketable securities were expected to fund operations for at least 12 months. It projected an increase in cash and cash equivalents of approximately $35 million to $55 million during 2016, subject to program spending, manufacturing scale-up, milestones and royalties; the projection included the January 2016 Lilly payment and royalty-backed loan. The filing provides no formal revenue or earnings guidance.
- Halozyme expected R&D spending to increase as PEGPH20 development advanced. It reported initiating the Phase 3 PEGPH20 study in stage IV PDA in early 2016 and completing enrollment of 133 patients in the Phase 2 study; mature Stage 2 PFS data and response results were projected for Q4 2016. These are forward-looking expectations, not reported outcomes.
- Interim Phase 2 findings in a small, retrospectively identified high-HA subgroup suggested improved PFS and response with PEGPH20 plus chemotherapy, but results were not conclusive. The Phase 3 program depends on a companion diagnostic and regulatory assessment of the benefit-risk profile.
- Safety is a key uncertainty: a 2014 clinical hold followed concern about thromboembolic (TE) events. The study resumed under a revised protocol with patient exclusions and anticoagulant prophylaxis; TE rates continued to be monitored, and further regulatory action remained possible.
- Other material risks include clinical or regulatory failure, manufacturing dependence on third parties, reliance on collaborators for development and commercialization, customer and royalty concentration, potential need for additional capital, dilution, and debt covenants or acceleration upon default. The company reported no legal proceeding expected by management to have a material adverse effect. Management and the auditor reported effective internal control over financial reporting; the financial statement audit opinion was unqualified.
Important facts for investors to verify
- Whether the PEGPH20 Phase 3 trial and its companion diagnostic achieve enrollment, safety and efficacy requirements, and whether high-HA subgroup findings are confirmed.
- Updated TE event data, anticoagulation practices, and any FDA or other regulator feedback affecting continued trials or approval requirements.
- Roche and Baxalta product sales, resulting royalty receipts, and the portion of those royalties directed to repayment of the $150 million loan.
- Cash burn, clinical and manufacturing commitments, and whether the stated liquidity runway and 2016 cash expectations remain achievable.
- Revenue quality and concentration: the extent to which upfront license fees, milestones and collaborator sales—not recurring product sales—drive reported results.